Nervamat (Ropinirole Hydrochloride)

Ropinirole stimulates dopamine D2 and D3 receptors in the brain, particularly in the basal ganglia. By activating these receptors, it enhances dopaminergic signaling, which compensates for dopamine deficiency in Parkinson's disease and modulates sensory‑motor pathways involved in restless legs syndrome.

The specific dose of Nervamat is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are typically made gradually to achieve the desired therapeutic effect while minimizing side effects.

Safety data for ropinirole in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nervamat, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nervamat (ropinirole) is a dopamine agonist, offering an oral alternative to levodopa or other agonists such as pramipexole. It may be preferred for patients who need continuous dopaminergic stimulation or who experience motor fluctuations with levodopa, though individual response varies.

Nervamat should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Nervamat is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks include hallucinations, impulse control disorders (such as compulsive gambling or shopping), severe hypotension, and sudden onset of sleep. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Nervamat is contraindicated in patients with known hypersensitivity to ropinirole or any of its excipients, and in individuals taking monoamine oxidase‑B inhibitors. Caution is also advised for patients with severe cardiovascular disease, uncontrolled psychiatric disorders, or significant renal impairment.